Avanza Fonder AB, Empirical Asset Management LLC, Fiduciary Financial Group LLC, Outlook Wealth Advisors LLC, Pines Wealth Management LLC and many others have increased their stakes in
Zoetis Inc. Though others like
Yarbrough Capital LLC, Carnegie Investment Counsel, HCR Wealth Advisors are reducing their holdings.
The average price target set by brokerages is
$211.89. Notably,
Zoetis has been predicted to outperform market returns and is considered a top-ranking growth stock. Retrieving expert advice,
Zoetis is a recommended Buy and is gaining market attention due to its strong growth attributes and R&D benefits. Earning projections for FY2024 has been made by
Leerink Partners. The company has been struggling in the market, losing about
18% over the last three years.
Zoetis will host its Q4 earnings report soon, with analysts foreseeing a positive earnings growth. Optimism is also noted surrounding the company's arthritis drug for dogs deemed safe.
Zoetis ZTS News Analytics from Tue, 06 Aug 2024 07:00:00 GMT to Sat, 18 Jan 2025 14:58:31 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor -5
